CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW

Objective: The aim of this review is to assess patients with chronic myeloid leukemia with concomitant JA2 positive for - their characteristics - response to treatment Methodology: We searched the English literature (Google Scholar, PubMed, and SCOPUS) for studies, reviews, case series, and case reports of patients with chronic myeloid leukemia who had JAK2 mutation. Inclusion criteria: were the presence of JAK2 mutation in CML patients with BCR-ABL1 rearrangement and, secondly, age ≥18yrs. The search included all articles published up to 20th April 2021. Results: A total of 25 patients met our criteria of the search. Twenty-two patients were diagnosed in the chronic phase, 2 patients in the accelerated phase, and one patient transformed to the blast phase. More females n=16 and 10 males. The mean age at the time of diagnosis was 61.3 years. 9 patients had to be switch to second-line therapy. Age and gender distribution and the presence of splenomegaly or organomegaly are almost the same. Males were slightly more than females. Conclusion: It is difficult to conclude that multi-kinase inhibitors are superior to imatinib in treating CML with concomitant JAK2 mutation. But the result of the reported cases showed that multi-kinase inhibitors are more likely to be successful in achieving remission and loss of JAK2 mutation. However, it is difficult to generalize the result without further studies due to the few numbers of patients and the unusual association